 |
 Video: What is a Stock Split?
|
|
|
| Alector is a clinical stage biopharmaceutical company developing immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. Co.'s product candidate, AL001, modulates progranulin (PRGN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders. AL101, Co.'s second product candidate in its PGRN portfolio, is designed to treat people suffering from more prevalent neurodegenerative diseases. AL003 is Co.'s second therapeutic candidate designed to treat patients with Alzheimer's disease. AL044 is Co.'s therapeutic candidate for neurodegeneration. According to our Alector stock split history records, Alector has had 0 splits. | |
|
Alector (ALEC) has 0 splits in our Alector stock split history database.
Looking at the Alector stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Alector shares, starting with a $10,000 purchase of ALEC, presented on a split-history-adjusted basis factoring in the complete Alector stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
02/08/2019 |
|
| End date: |
05/03/2024 |
|
| Start price/share: |
$16.30 |
|
| End price/share: |
$5.39 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-66.93% |
|
| Average Annual Total Return: |
-19.06% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$3,306.96 |
|
| Years: |
5.23 |
|
|
|
|
|
